Canadian cannabis producer Canopy Growth has announced its entry into the UK medical cannabis market, with four Canadian-grown medical cannabis flower strains set to be supplied to the UK through British manufacturer and distributor GROW Group.
The announcement, made on 22 September 2026, will see the products marketed in the UK under Canopy Growth’s Spectrum Therapeutics medical cannabis brand. According to the company, the initial launch represents the introduction of its portfolio into the UK market.
The flower will be supplied from Canopy Growth’s Kincardine cultivation facility in Ontario, Canada, which received renewed European Union Good Manufacturing Practice (EU-GMP) certification in August. The certification allows the facility to continue supplying Canadian-grown cannabis to medical markets across Europe.
Canadian cultivation supplying the UK
The development highlights the increasingly international nature of the medical cannabis supply chain, with cultivation, pharmaceutical manufacturing and distribution taking place across different jurisdictions.
For Canopy Growth, the UK represents another European market for its Canadian-grown medical cannabis. The company says the Kincardine facility’s EU-GMP certification supports its ability to supply medical cannabis markets across Europe, while the new agreement with GROW Group provides a route into the UK.
GROW Group is a UK-based manufacturer and distributor of prescribed cannabis-based medicines across Europe. The four flower strains will be commercialised in the UK through the company’s existing operations.
What does this mean for UK cultivation?
The announcement comes against a backdrop of continued development within the UK’s own medical cannabis cultivation and production sector.
Cannabis cultivation in the UK remains subject to Home Office licensing. Government guidance states that companies wishing to cultivate cannabis to produce cannabis-based products for medicinal use must obtain the appropriate licence, with applications considered individually alongside other regulatory requirements.
The UK medical cannabis framework also distinguishes medicinal cannabis from recreational cannabis. Cannabis-based products for medicinal use can be prescribed by specialist doctors under the UK’s regulatory framework, while companies involved in activities including possession, manufacture, supply, import or export may require controlled-drug licences.
This regulatory environment means that commercial medicinal cannabis production is considerably different from conventional horticultural production. Growers must operate within a controlled and highly regulated supply chain, with cultivation, processing, testing, manufacturing and distribution all forming part of the route from plant to prescribed medicine.
EU-GMP and controlled-environment cultivation
For commercial growers, one of the most significant elements of the Canopy announcement is the role of EU-GMP certification.
Good Manufacturing Practice is concerned with ensuring that medicinal products are consistently produced and controlled according to appropriate quality standards. For cannabis businesses supplying European medical markets, meeting pharmaceutical-grade requirements is therefore an important part of establishing an international supply chain.
Canopy’s Kincardine facility was originally established as a large-scale cannabis cultivation site, and its continued EU-GMP certification allows production there to feed into regulated medical cannabis markets outside Canada.
The development illustrates how commercial cannabis cultivation increasingly sits at the intersection of horticulture and pharmaceutical manufacturing. Environmental control, crop consistency, traceability and quality management are all important considerations for growers producing material destined for medicinal products.
A developing UK market
Medical cannabis has been legally prescribable in the UK since November 2018, when cannabis-based products for medicinal use were moved into Schedule 2 of the Misuse of Drugs Regulations. Specialist doctors can prescribe these products where clinically appropriate.
The sector continues to develop, with the UK’s Advisory Council on the Misuse of Drugs currently reviewing the impact of the 2018 changes. The ACMD opened a call for evidence in September 2025 covering issues including the experiences of healthcare professionals, researchers, importers, manufacturers, patients and regulatory bodies.
For the horticulture industry, Canopy Growth’s UK launch provides another example of how medicinal cannabis cultivation is becoming part of a wider international controlled-environment growing industry. As companies establish supply chains between licensed cultivation facilities and European medical markets, the requirements around crop quality, consistency, traceability and pharmaceutical manufacturing are likely to remain central to the sector.
With four Canadian-grown flower strains now being introduced to the UK through GROW Group, the latest development adds another international supplier to an evolving British medical cannabis market.
Sources: Canada Growth, UK Gov.
Leave a Reply